Fred Askari

1.5k total citations
18 papers, 978 citations indexed

About

Fred Askari is a scholar working on Nutrition and Dietetics, Health, Toxicology and Mutagenesis and Infectious Diseases. According to data from OpenAlex, Fred Askari has authored 18 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Nutrition and Dietetics, 9 papers in Health, Toxicology and Mutagenesis and 4 papers in Infectious Diseases. Recurrent topics in Fred Askari's work include Trace Elements in Health (12 papers), Heavy Metal Exposure and Toxicity (9 papers) and Infectious Encephalopathies and Encephalitis (4 papers). Fred Askari is often cited by papers focused on Trace Elements in Health (12 papers), Heavy Metal Exposure and Toxicity (9 papers) and Infectious Encephalopathies and Encephalitis (4 papers). Fred Askari collaborates with scholars based in United States, Denmark and Iran. Fred Askari's co-authors include George J. Brewer, Robert Dick, Karen J. Kluin, John K. Fink, Martha Carlson, Peter Hedera, Matthew T. Lorincz, Jorge A. Marrero, Sherry Fu and Anna S. Lok and has published in prestigious journals such as Gastroenterology, Journal of Hepatology and Experimental Biology and Medicine.

In The Last Decade

Fred Askari

17 papers receiving 950 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fred Askari United States 9 620 408 187 187 174 18 978
Nabeel F. Adham United States 16 225 0.4× 51 0.1× 34 0.2× 35 0.2× 61 0.4× 33 580
Masaki Takayanagi Japan 23 155 0.3× 64 0.2× 30 0.2× 63 0.3× 85 0.5× 78 1.3k
Bill L. Kreamer United States 15 42 0.1× 120 0.3× 50 0.3× 139 0.7× 87 0.5× 34 1.3k
Robert Dick United States 12 223 0.4× 98 0.2× 57 0.3× 21 0.1× 15 0.1× 30 444
S. Theocharis Greece 10 243 0.4× 128 0.3× 14 0.1× 31 0.2× 49 0.3× 13 498
Lydia Álvarez Spain 14 136 0.2× 78 0.2× 14 0.1× 14 0.1× 18 0.1× 37 624
Y. Naitoh Japan 11 41 0.1× 28 0.1× 49 0.3× 55 0.3× 38 0.2× 22 519
Ameen A. Salahudeen United States 12 114 0.2× 16 0.0× 76 0.4× 12 0.1× 50 0.3× 31 787
Liv Endresen Norway 13 281 0.5× 156 0.4× 44 0.2× 8 0.0× 17 0.1× 23 601
Akihiko Kimura Japan 19 63 0.1× 22 0.1× 23 0.1× 89 0.5× 151 0.9× 83 1.1k

Countries citing papers authored by Fred Askari

Since Specialization
Citations

This map shows the geographic impact of Fred Askari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Askari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Askari more than expected).

Fields of papers citing papers by Fred Askari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Askari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Askari. The network helps show where Fred Askari may publish in the future.

Co-authorship network of co-authors of Fred Askari

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Askari. A scholar is included among the top collaborators of Fred Askari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Askari. Fred Askari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ala, Aftab, Fred Askari, Karl Heinz Weiss, Valentina Medici, & Thomas Damgaard Sandahl. (2025). Oral bis-choline tetrathiomolybdate rapidly improves copper balance in patients with Wilson disease. Journal of Hepatology. 83(6). e271–e273.
2.
Weiss, Karl Heinz, Thomas Damgaard Sandahl, Valentina Medici, et al.. (2025). LBP-032 Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline. Journal of Hepatology. 82. S86–S87. 1 indexed citations
3.
Sandahl, Thomas Damgaard, William M. Lee, Aftab Ala, et al.. (2024). WED-164 Interim safety results of the ongoing international phase I/II GATEWAY gene therapy trial with VTX-801 conducted in adult patients with Wilson disease. Journal of Hepatology. 80. S714–S715. 1 indexed citations
4.
Weiss, Karl Heinz, Michael L. Schilsky, Anna Członkowska, et al.. (2022). Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. Journal of Hepatology. 77. S1–S1. 4 indexed citations
5.
Weiss, K.H., Fred Askari, Péter Ferenci, et al.. (2018). Long-term efficacy and safety of WTX101 in Wilson disease: Data from an ongoing extension of a phase 2 study (WTX101-201). Journal of Hepatology. 68. S105–S105. 1 indexed citations
6.
Askari, Fred, et al.. (2018). The effect of 8 weeks beta-alanine supplementation and resistance training on maximal-intensity exercise performance adaptations in young males. Physical Education of Students. 23(1). 4–8. 4 indexed citations
7.
Weiss, K.H., Fred Askari, Péter Ferenci, et al.. (2017). WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trial. Journal of Hepatology. 66(1). S88–S88. 6 indexed citations
8.
Singal, Amit G., Hari S. Conjeevaram, Michael L. Volk, et al.. (2012). Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Cancer Epidemiology Biomarkers & Prevention. 21(5). 793–799. 196 indexed citations
9.
Burke, James, Praveen Dayalu, Bin Nan, et al.. (2011). Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism & Related Disorders. 17(7). 551–556. 33 indexed citations
10.
Askari, Fred, Robert Dick, Guoqing Hou, et al.. (2009). Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial. Translational research. 155(3). 123–130. 20 indexed citations
11.
Brewer, George J., Fred Askari, Robert Dick, et al.. (2009). Treatment of Wilson's disease with tetrathiomolybdate: V. control of free copper by tetrathiomolybdate and a comparison with trientine. Translational research. 154(2). 70–77. 127 indexed citations
12.
Brewer, George J., Fred Askari, Matthew T. Lorincz, et al.. (2007). Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease. 3(1). 1 indexed citations
13.
Brewer, George J., Fred Askari, Matthew T. Lorincz, et al.. (2006). Treatment of Wilson Disease With Ammonium Tetrathiomolybdate. Archives of Neurology. 63(4). 521–521. 207 indexed citations
14.
Brewer, George J. & Fred Askari. (2004). Wilson's disease: clinical management and therapy. Journal of Hepatology. 42(1). S13–S21. 93 indexed citations
15.
Askari, Fred, et al.. (2004). Tetrathiomolybdate Therapy Protects Against Concanavalin a and Carbon Tetrachloride Hepatic Damage in Mice. Experimental Biology and Medicine. 229(8). 857–863. 27 indexed citations
16.
Brewer, George J., Peter Hedera, Karen J. Kluin, et al.. (2003). Treatment of Wilson Disease With Ammonium Tetrathiomolybdate. Archives of Neurology. 60(3). 379–379. 184 indexed citations
17.
Askari, Fred, Joel K. Greenson, Robert D. Dick, Virginia Johnson, & George J. Brewer. (2003). Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. Journal of Laboratory and Clinical Medicine. 142(6). 385–390. 72 indexed citations
18.
Todisco, Andrea, et al.. (2000). Functional role of protein kinase Akt in gastric acid secretion. Gastroenterology. 118(4). A713–A713. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nabeel F. Adham Breakdown of academic impact, for papers by Masaki Takayanagi Breakdown of academic impact, for papers by Bill L. Kreamer Breakdown of academic impact, for papers by Robert Dick Breakdown of academic impact, for papers by S. Theocharis Breakdown of academic impact, for papers by Lydia Álvarez Breakdown of academic impact, for papers by Y. Naitoh Breakdown of academic impact, for papers by Ameen A. Salahudeen Breakdown of academic impact, for papers by Liv Endresen Breakdown of academic impact, for papers by Akihiko Kimura
Rankless by CCL
2026